Coronary artery disease remains the leading cause of mortality worldwide, and percutaneous coronary intervention with stent implantation has revolutionized its management. Despite significant advancements from bare metal stents to drug-eluting stents, challenges such as in-stent restenosis, delayed endothelialization, and late stent thrombosis persist. Nanotechnology offers promising solutions through nanoparticle-based drug delivery systems, nanocoatings, and molecular targeting strategies that may achieve restenosis prevention while preserving endothelial healing. This narrative review examines the evolution of coronary stent technology, the pathophysiology of in-stent restenosis, and the application of nanotechnology in contemporary stent design. We discuss various nanoparticle platforms including liposomes, polymeric nanoparticles, and magnetic nanoparticles, along with their mechanisms of targeted drug delivery to the vascular wall. Furthermore, we review preclinical studies and early clinical trials of nanoparticle-enhanced stents, analyze current challenges in clinical translation, and outline future directions for this rapidly evolving field.

Nanoplasty; Nanotechnology; Coronary stent; Drug-eluting stent; In-stent restenosis; Nanoparticle; Molecular targeting; Cardiovascular disease; Percutaneous coronary intervention; Endothelialization

World Health Organization. Cardiovascular Diseases Fact Sheet. Geneva: WHO Press; 2023.

Gruentzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med. 1979;301(2):61-68.

Sigwart U, Puel J, Mirkovitch V, Joffre F, Kappenberger L. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med. 1987;316(12):701-706.

Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994;331(8):489-495.

Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349(14):1315-1323.

Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350(3):221-231.

Windecker S, Serruys PW, Wandel S, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet. 2008;372(9644):1163-1173.

Byrne RA, Stefanini GG, Capodanno D, et al. Duration of dual antiplatelet therapy in patients treated with coronary stents: an update. Eur Heart J. 2015;36(24):1512-1523.

Masuda S, Ozaki Y, Okada M, et al. Nanoparticle-mediated delivery of mitomycin C circumvents simultaneous resistance to free drugs in vascular smooth muscle cells. J Vasc Res. 2011;48(4):301-310.

Danenberg HD, Golomb G, Groothuis A, et al. Liposomal alendronate inhibits systemic innate immunity and reduces in-stent neointimal hyperplasia in rabbits. Circulation. 2003;108(22):2798-2804.

Bhargava B, Reddy NK, Mishra S, et al. Novel drug delivery system for paclitaxel using porous carbon-carbon nanoparticles coated on nonpolymeric cobalt-chromium stent. JACC Cardiovasc Interv. 2013;6(5):514-522.

Chorny M, Fishbein I, Yellen BB, et al. Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields. Proc Natl Acad Sci USA. 2010;107(18):8346-8351.

Yang Y, Zhang L, Chiu PC, et al. VEGF/PDGF dual-targeting nanoparticle stent coating simultaneously promotes re-endothelialization and inhibits restenosis. Biomaterials. 2013;34(23):5735-5747.

Chan JM, Rhee JW, Drum CL, et al. Collagen-targeting nanoburrs deliver therapeutics to the arterial wall more efficiently than free drugs. Proc Natl Acad Sci USA. 2011;108(48):19345-19350.

Joner M, Morimoto K, Kasukawa H, et al. Site-specific targeting of magnetic nanoparticles to iron-phosphate for treatment of vascular injury. Biomaterials. 2011;32(5):1422-1431.

Alexander GC, Vines JB, Hwang P, et al. Nanomatrix coated stent enhances endothelialization but reduces platelet, smooth muscle cell, and monocyte adhesion under physiologic conditions. ACS Appl Mater Interfaces. 2019;11(38):35225-35238.

Gaspar R. Nanoparticles in medicine: from laboratory to bed-side challenges. Int J Nanomedicine. 2007;2(2):143-147.

Tinkle S, McNeil SE, Muhlebach S, et al. Nanomedicines: addressing the scientific and regulatory gap. Ann N Y Acad Sci. 2014;1313(1):35-56.